A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
This trial is active, not recruiting.
|Condition||unresectable stage iii or stage iv melanoma|
|Treatments||combination of varlilumab and ipilimumab, cohort a: varlilumab & ipilimumab; cohort b: varlilumab, ipilimumab, cdx-1401 & poly-iclc|
|Phase||phase 1/phase 2|
|Start date||April 2015|
|End date||January 2017|
|Trial size||9 participants|
|Trial identifier||NCT02413827, CDX1127-03|
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining a) varlilumab and ipilimumab and b) varlilumab, ipilimumab, CDX-1401 and poly-ICLC. The study will enroll patients with unresectable Stage III or Stage IV melanoma.
|Other Countries||No locations recruiting|
|San Francisco, CA||California Pacific Medical Center Research Institute||no longer recruiting|
|Santa Rosa, CA||Sutter Pacific Medical Foundation||no longer recruiting|
|Aurora, CO||University of Colorado Cancer Center - Anschutz Cancer Pavilion||approved|
|Washington DC, DC||Georgetown University School of Medicine||no longer recruiting|
|Chicago, IL||University of Chicago Comprehensive Cancer Center||recruiting|
|Saint Louis, MO||Siteman Cancer Center at Washington University||in review|
|St. Louis, MO||Washington University School of Medicine||no longer recruiting|
|Pittsburgh, PA||University of Pittsburgh Cancer Institute (UPCI)||approved|
|Nashville, TN||Tennessee Oncology Sarah Cannon Research Institute||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Phase l: Safety and tolerability of varlilumab in combination with ipilimumab as measured by incidences of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities and laboratory test abnormalities.
time frame: Safety follow-up is 70 days from last study drug dose.
Phase ll: The objective response rate (ORR) is defined as the proportion of patients who achieve radiographic partial or complete response (PR or CR) according to the mWHO tumor response criteria.
time frame: Up to 24 weeks
Male or female participants at least 18 years old.
Key Inclusion Criteria: 1. Histologic diagnosis of melanoma. 2. Unresectable Stage III or IV disease 3. Documented progressive disease based on radiographic, clinical or pathologic assessment. 4. No more than three prior anticancer regimens (BRAF/MEK inhibitors, IL-2 or investigational agents) including no more than one chemotherapy-containing regimen for advanced (recurrent, locally advanced or metastic) disease. 5. Measurable disease. 6. Life expectancy ≥ 12 weeks. 7. If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 70 days following last treatment. 8. Availability of tumor tissue for central laboratory analyses. Key Exclusion Criteria: 1. Previous treatment with anti-CD27 antibody, ipilimumab or other anti-CTLA-4 targeted therapies. Previous therapy with other checkpoint blockers such as anti-PD-1 or anti-PD-L1 is acceptable, unless treatment was discontinued for intolerance. 2. For patients enrolled to Phase II Cohort B: Previous administration of vaccine therapy targeting NY-ESO-1. 3. BRAF/MEK inhibitors within 2 weeks prior to first dose of study treatment. 4. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to first dose of study treatment. 5. Monoclonal based therapies within 4 weeks and all other immunotherapy within 2 weeks prior to first dose of study treatment. 6. Systemic radiation therapy within 4 weeks, focal radiotherapy within 2 weeks and radiopharmaceuticals (strontium, samarium) within 8 weeks prior to first dose of study treatment. 7. Ocular Melanoma 8. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers; or any other cancer from which the patient has been disease-free for at least 3 years. 9. Active, untreated central nervous system metastases. 10. Active autoimmune disease or documented history of autoimmune disease. 11. Active diverticulitis 12. Significant cardiovascular disease including CHF or poorly controlled hypertension.
|Official title||A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma|
|Description||Varlilumab is a fully human monoclonal antibody that binds to a molecule called CD27 found on certain immune cells and may act to promote anti-tumor effects. Yervoy™ (Ipilimumab) is a human monoclonal antibody that blocks CTLA-4, a protein receptor that downregulates the immune system. CDX-1401 is a vaccine made of a fully human monoclonal antibody linked to NY-ESO-1 and is designed to deliver NY-ESO-1 to professional antigen presenting cells for generating robust immune responses against cancer cells expressing NY-ESO-1. CDX-1401 is administered with poly-ICLC, an adjuvant that enhances vaccine-induced immune responses. This study will evaluate the safety, tolerability and efficacy of varlilumab and ipilimumab, with or without the addition of CDX-1401/poly-ICLC, in patients with melanoma. Eligible patients that enroll in the Phase I portion of the study will be assigned to one of two possible dose levels of varlilumab in combination with 3 mg/kg ipilimumab. The first phase of the study will test the safety profile of the combination and determine which dose of varlilumab will be studied in Phase II of the study. During Phase II, up to 48 patients whose tumors do not express NY-ESO-1, will receive the recommended dose of varlilumab determined from Phase I with 3 mg/kg ipilimumab. Up to 24 patients whose tumors express NY-ESO-1 will receive the recommended dose of varlilumab combined with 3 mg/kg ipilimumab and 1 mg CDX-1401 along with 2 mg poly-ICLC. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.|
Call for more information